Disclaimer: Whilst we always aim to provide accurate information, Recite Me uses machine translation so the translation may not be perfect and we can’t guarantee its accuracy. Myeloma UK accepts no liability for any inaccuracies resulting from the use of this translation tool. The information provided is not meant to replace the advice of your healthcare team. Find out more about this tool at reciteme.com
The British Society for Haematology (BSH) Annual Scientific Meeting takes place in Liverpool from 19 to 21 April 2026. The programme includes several sessions directly relevant to myeloma care, clinical decision-making and research, making it a valuable meeting for consultants, CNSs, pharmacists and allied teams involved in myeloma pathways.
What to expect for myeloma practice
The programme features updates across plasma cell disorders, with sessions covering:
New and emerging myeloma treatments in UK clinical practice.
Translational research informing risk stratification and disease monitoring.
Supportive care and management of treatment-related complications.
Myeloma in older and less fit patients, including real-world considerations.
Myeloma nursing practice, patient communication and service pressures.
Abstract presentations showcasing UK and international research in myeloma biology, treatment sequencing and outcomes.
These sessions provide a consolidated view of current evidence, upcoming changes in practice and practical considerations for day-to-day care.
–
